Logo Annals of Transplantation Logo Annals of Transplantation Logo Annals of Transplantation

Clinical immunosuppression – current status

M. Klinger

Ann Transplant 2008; 13(1): 11-11 :: ID: 880166

Abstract

The current immunosuppressive regimens allow to achieve the excellent one year organ survival, exceeding in renal transplantation 90%, with acute rejection rate below 15%. However, this medal has the reverse side, and it is price to pay. 54% of the kidney allograft is lost due to the recipient death with the functioning graft, mainly due to cardiovascular diseases, infection and malignancy. 40% of the graft failure is caused by chronic allograft injury (CAI) which encompasses calcineurin inhibitor nephrotoxicity, chronic rejection, and toxicity occurring simultaneously with inadequate, not controlling alloresponse immunosuppression. The present strategies of initial post transplantation immunosuppressive treatment are diversified based on the evaluation of the recipient immunologic risk and of the delayed graft function occurrence threat. For low immunologic risk recipients, calcineurin inhibitor containing regimen; with or without anti CD25 antibody are recommended. High immunologic risk recipients are treated by polyclonal anti T-cell antibodies, with subsequent calcineurin inhibitor introduction. The polyclonal anti T-cell antibodies are also administrated in the delayed graft function appearance or when expectation for it's appearance is high. The main long-term goal in the post transplantation immunosuppressive treatment is to achieve the balance between efficacy and toxicity of the immunosuppressive regimen, with the reduction of the overall side effect "load" on patients. For that purpose two general approach are applied: corticosteroid withdrawal and avoidance protocols, and calcineurin inhibitor withdrawal/minimization protocols.

Keywords: Transplantation, Cardiovascular Diseases, nephrotoxicity

Comments

In Press

06 May 2022 : Original article  

Phosphatidylethanol (PEth) for Monitoring Sobriety in Liver Transplant Candidates: Preliminary Results of D...

Ann Transplant In Press; DOI: 10.12659/AOT.936293  

27 Apr 2022 : Review article  

A Systematic Review of the Literature on Chronic Kidney Disease Following Liver Transplantation

Ann Transplant In Press; DOI: 10.12659/AOT.935170  

Most Viewed Current Articles

31 Dec 1969 : Original article  

Efficacy and Safety of Tacrolimus-Based Maintenance Regimens in De Novo Kidney Transplant Recipients: A Sys...

DOI :10.12659/AOT.933588

Ann Transplant 2021; 26:e933588

31 Dec 1969 : Review article  

Recurrence of Hepatocellular Carcinoma After Liver Transplantation: Risk Factors and Predictive Models

DOI :10.12659/AOT.934924

Ann Transplant 2022; 27:e934924

31 Dec 1969 : Review article  

Kidney Transplantation in the Times of COVID-19 – A Literature Review

DOI :10.12659/AOT.925755

Ann Transplant 2020; 25:e925755

31 Dec 1969 : Case report  

Combined Liver, Pancreas-Duodenum, and Kidney Transplantation for Patients with Hepatitis B Cirrhosis, Urem...

DOI :10.12659/AOT.935860

Ann Transplant 2022; 27:e935860

Your Privacy

We use cookies to ensure the functionality of our website, to personalize content and advertising, to provide social media features, and to analyze our traffic. If you allow us to do so, we also inform our social media, advertising and analysis partners about your use of our website, You can decise for yourself which categories you you want to deny or allow. Please note that based on your settings not all functionalities of the site are available. View our privacy policy.

Annals of Transplantation eISSN: 2329-0358
Annals of Transplantation eISSN: 2329-0358